Table 2.
Principal Phase Ib–II trials on MET-TKI in MET-amplified EGFR-mutated advanced NSCLC patients.
| Drug | Trial | Phase | Therapy Line * | Prior Treatment | Treatment Arm | N pts | Main Results | Status |
|---|---|---|---|---|---|---|---|---|
| Single agent | ||||||||
| Capmatinib | GEOMETRY -mono-1 (NCT02414139) |
II | ≥2L | NA | Capmatinib | 69 | ORR = 29% mDOR = 8.3 mo mPFS = 4.1 mo |
Ongoing |
| Combinations | ||||||||
| Tepotinib | INSIGH (NCT01982955) |
Ib/II | 2L | 1G-2G EGFR-TKIs |
Tepotinib + Gefitinib vs. Platinum-based CT |
19 | ORR = 67% vs. 43% mPFS = 16.6 vs. 4.2 mo mOS = 37.3 vs. 13.1 mo |
Closed |
| Capmatinib | NCT01610336 | II | 2L | Gefitinib/ Erlotinib |
Capmatinib + Gefitinib |
100 | ORR = 47% | Closed |
| Cabozantinib | NCI 9303 II (NCT01866410) | II | ≥2L | 1G, 2G, 3G EGFR-TKIs |
Cabozantinib + Erlotinib |
37 | ORR = 10.8% mPFS = 3.6 mo mOS = 13.1 mo |
Closed |
2L—second-line; NA—not available; 1G—first-generation; 2G—second-generation; EGFR—epidermal growth factor receptor; TKI—tyrosine kinase inhibitor; CT—chemotherapy; N—number; pts—patients; ORR—overall response rate; mo—month; mDOR—median duration of response; mPFS—median progression-free survival; vs.—versus; mOS—median overall survival. An asterisk (*) indicates the line or lines of treatment for advanced NSCLC in which the investigational agent or regimen was employed in each reported trial.